GSK’s Nuvalent buyout delivered again as the FDA cleared neladalkib (Nelkarmi) for accelerated approval in lung cancer, per a report tied to the company’s Nuvalent acquisition. The drug is one of two assets at the center of GSK’s $10.6 billion purchase of Nuvalent earlier this year. For oncology pipeline managers, the move signals continued regulatory openness to accelerated pathways—while also emphasizing how quickly acquired assets can translate into commercial milestones.
Get the Daily Brief